<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the outcomes of patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> diagnosed with <z:hpo ids='HP_0011009'>acute</z:hpo> invasive Aspergillus <z:e sem="disease" ids="C0948780" disease_type="Disease or Syndrome" abbrv="">rhinosinusitis</z:e> comparing a group of patients diagnosed after <z:chebi fb="0" ids="10023">voriconazole</z:chebi> was available at our center with a historical group of patients diagnosed before <z:chebi fb="0" ids="10023">voriconazole</z:chebi> was available </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="10023">Voriconazole</z:chebi> use was associated with a decrease in mortality and earlier clinical response </plain></SENT>
</text></document>